Germany Pharmaceuticals Market Size, Share & Trends Analysis Report By Drug Class (Anti-cancer, Anti-viral, Anti-diabetics, Anti-rheumatics), By Type, By Formulation, By Application, And Segment Forecasts, 2020 - 2027

Report Overview 

The Germany pharmaceuticals market size was valued at USD 41.4 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2020 to 2027. Increasing patent applications that are focused on the development of novel drug delivery systems, new drugs, and formulations is anticipated to boost the market for pharmaceuticals. According to the European Patent Office (EPO) Patent Index 2019, the number of patent applications increased by 4.4% in 2018 in the pharmaceutical field. Therefore, growth in patent applications is estimated to accelerate innovations in the pharmaceutical industry. Furthermore, the growing export of pharmaceuticals from the Federal Republic of Germany to various countries is anticipated to boost the growth of the market for pharmaceuticals. For instance, according to the German Pharmaceutical Industry Association (BPI), in 2018, pharmaceuticals worth USD 98.6 billion were exported from Germany.

This corresponds to an increase of 10.3% over the previous year. Furthermore, the U.S., Netherlands, and Switzerland are the top three main customers for pharmaceuticals from Germany. Favorable reimbursement scenario and pricing for pharmaceuticals companies &customers are expected to fuel the growth of the market for pharmaceuticals. For instance, in Germany, 90% of the population is covered from Statutory Health Insurance (SHI) and the remaining 10.0% is covered by special schemes and private insurance.

The presence of strong pipeline drugs in Phase III clinical trials are expected to be commercialized over the forecast period, thereby, driving the growth of the market for pharmaceuticals. For instance, Boehringer Ingelheim International GmbH’s R & D pipeline consists of two candidates namely Empagliflozin and Nintedanib under phase III clinical trial for cardiovascular diseases and respiratory diseases.

Drug Class Insights

The anti-cancer segment accounted for the largest revenue share of 15.6% in 2019 due to the increasing prevalence of cancer and the commercialization of novel therapies to treat various types of cancers. For instance, according to GLOBOCAN 2018, there were 71, 888 new cases of breast cancer, followed by lung cancer with 66,749 new cases, and 62,641 new prostate cancer cases.

Key players are developing new drugs to combat the rising cases of cancer, thereby, accelerating the market for pharmaceuticals. For instance, in March 2020, Nubeqa (darolutamide) received marketing authorization from the European Commission. The compound is an oral Androgen Receptor inhibitor (ARi) developed by Bayer in collaboration with Orion Corporation to treat non-metastatic castration-resistant prostate cancer (nmCRPC).

Increasing research initiatives to develop novel drugs for treatment against different viruses is expected to boost the Germany pharmaceuticals market. For instance, in March 2020, a study was published by a group of scientists from Germany that demonstrated the use of Camostat Mesylate against COVID-19 caused by SARS–CoV-2 coronavirus. The study found that SARS-CoV-2 requires a cellular protein TMPRSS2 in the human body to enter host cells. Therefore, the Japanese FDA approved the drug Camostat Mesylate which is active against coronavirus and has the potential to block TMPRSS2.

Type Insights

The branded drugs segment dominated the market for pharmaceuticals and accounted for the largest revenue share in 2019. Increasing R&D efforts, increased adoption of novel therapies, and strategic collaborations driving wide-scale penetration of drugs are few contributing factors for the growth of this segment.

However, the emergence of biosimilars has heralded a significant shift in the cancer treatment landscape in Germany. The expiration of patent exclusivities and rising need for cost-effective drugs are fueling the penetration of biosimilars and generic drugs into the market for pharmaceuticals. Therefore, generic drugs are estimated to be the fastest-growing segment during the forecast period. Furthermore, key players are acquiring a generic product portfolio to acquire a higher market share in the generic market over the forecast period. For instance, in February 2020, STADA AG acquired GlaxoSmithKline plc’s consumer healthcare brands such as Venoruton, Tavegyl allergy brand, Mebucaine sore throat range, Cetebe vitamin C supplements, and Coldrex cold remedy.

Formulations Insights

The solid formulation segment is expected to witness a significant CAGR owing to its cost-effectiveness and several other benefits associated with its administration. In addition, local players undergoing strategic initiatives such as collaboration and licensing to expand their presence in new regions is anticipated to drive the market for pharmaceuticals in Germany.

For instance, in December 2019, Bausch Health Companies Inc. & Bausch + Lomb acquired an exclusive license to commercialize and develop Novaliq GmbH’s investigational candidate NOV03 (perfluorohexyloctane). NOV03 is a solution for the treatment of DED associated with Meibomian gland dysfunction (MGD)

Application Insights

Oncology accounted for the largest revenue share of 15.5% in 2019 owing to increasing strategic initiatives such as collaboration, partnership, & others to develop & strengthen their portfolio. For instance, in September 2019, Boehringer Ingelheim International GmbH and Lupin Ltd entered into a partnership to license, develop, and commercialize Lupin’s MEK inhibitor compound (LNP3794) for the treatment of cancers. Under the agreement, Boehringer Ingelheim will develop innovative KRAS inhibitors in combination with Lupin’s lead MEK inhibitor compound for gastrointestinal and lung cancers.

Furthermore, companies have developed new drugs to increase the availability of prescription drugs which is anticipated to accelerate the market for pharmaceuticals in Germany. For instance, in March 2019, Rubraca was made available in Germany as a prescription drug for ovarian cancer, developed by Clovis Oncology, Inc.

Key Companies & Market Share Insights

Key players are focusing on the development and approval of new vaccines for infectious diseases in order to maintain a significant share in the market for pharmaceuticals in Germany. For instance, in November 2019, Merck Sharp and Dohme Corporation’s ERVEBO vaccine was approved by the EU Commission against the Zaire Ebola virus for people of age 18 years and above. Some of the prominent players in the Germany pharmaceuticals market include:

• Boehringer Ingelheim International GmbH

• Bayer AG

• Merck & Co., Inc.

• Fresenius Kabi AG

• STADA Arzneimittel AG

• Pfizer Inc.

• Abbott

• Abbvie Inc.

• Teva Pharmaceutical Industries Ltd.

• Novartis AG

Germany Pharmaceuticals Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-markets from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the Germany pharmaceuticals market on the basis of drug class, application, type, and formulation:

• Drug Class Outlook (Revenue, USD Million, 2016 - 2027)

  • Anti-cancer

  • Anti-diabetics

  • Anti-rheumatics

  • Vaccines

  • Anti-viral

  • Immunosuppressant

  • Bronchodilators

  • Dermatological

  • Anti-hypertensive

  • Others

• Application Outlook (Revenue, USD Million, 2016 - 2027)

  • Oncology

    • Breast cancer

    • Lung cancer

    • Colorectal cancer

    • Ovarian cancer

    • Prostate cancer

    • Others

  • Infectious Diseases

  • Cardiovascular Diseases

  • Central Nervous System Disorders

  • Immunological Disorders

  • Metabolic Disorders

  • Gastrointestinal Disorders

  • Respiratory Diseases

  • Ophthalmology

  • Dermatology Disorders

  • Others

• Type Outlook (Revenue, USD Million, 2016 - 2027)

  • Branded

  • Generics

• Formulation Outlook (Revenue, USD Million, 2016 - 2027)

  • Solid formulation

    • Tablets

    • Capsules

    • Others

  • Liquid & semi-liquid formulation

    • Oral

    • Topical

    • Sublingual and buccal

    • Rectal

    • Parenteral